World News

The companies are competing for a share of India’s Semaglutide market, which analysts estimate will reach USD1 billion over the next two years.

This transaction grants Collegium a second branded ADHD medication to complement its existing Jornay PM offering.

Psoriasis is a chronic autoimmune disorder in which skin cells multiply excessively, creating thick, itchy, scaly patches that affect more than 8 million Americans.

Novartis will direct the funds toward upgrading its manufacturing plant in Beijing and expanding its R&D campus in Shanghai, where it also houses its Chinese headquarters.

The transaction, which remains subject to customary regulatory approvals, marks the beginning of what both firms describe as Syntegon’s next major growth phase.

Construction crews have already broken ground on the expansion project, which Axplora expects to complete by February 2027.

GlobalData analysis projects that the global nephrology and urology device market, which includes BPH treatments, will reach almost USD12 billion in 2035, up from around USD8.6 billion in 2024.

The acquisition involves Novartis purchasing Pikavation Therapeutics, a wholly owned subsidiary of Synnovation Therapeutics that holds the rights to SNV4818 and related research programs.

The new production hub will be located in the Lin-gang Special Area of the Shanghai Free Trade Zone, where it will supply autologous CAR-T therapies to China and other Asian markets.

TPI’s new East Coast plant will complement its existing facility in Everett, Washington, where the company is also expanding capacity.